Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
naltrexone + naltrexone extended-release
- Development stage
- Unknown
- Lead developer
- Alkermes
- Modality
- Small Molecules
- Administration
- Oral, Intramuscular
01
Overview
Naltrexone + naltrexone extended-release is a combination of two formulations of the same active pharmaceutical ingredient, naltrexone. Naltrexone is an opioid receptor antagonist that works by binding to and blocking opioid receptors in the brain, thereby reducing cravings and preventing the euphoric and sedative effects of opioids and alcohol. The oral formulation is typically taken daily for alcohol use disorder (AUD), while the extended-release injectable formulation (XR-NTX) is administered intramuscularly once every four weeks for both AUD and opioid use disorder (OUD). Both forms are non-addictive, do not cause withdrawal symptoms upon discontinuation, and have no abuse potential. Extended-release formulations provide more consistent plasma levels compared to oral dosing[1][2][3][7]. The primary indications are AUD and OUD.
- Brand names
- Vivitrol
- Other names
- XR-NTXextended-release injectable naltrexoneoral naltrexone
02
Targets
DOR (Opioid Receptor Delta 1)MOR (Mu opioid receptor)KOR (Kappa opioid receptor)
Beyond the preview
Go deeper on naltrexone + naltrexone extended-release.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on naltrexone + naltrexone extended-release.